Keystone Biologics, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Keystone Biologics, Inc.
Scrip Asks…What Does 2023 Hold For Biopharma? Part 5: Technological Advances
The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.
Deal Watch: AZ, Alchemab To Study Immune Response For Novel Cancer Targets
Also, deals involving AbCellera/Angios, AstraZeneca/Alchemab, Kowa/Esteve, OSE/Veloxis, Tris/Park, Core One/Akome and Vertex/Obsidian.
Eberhard Grube: European Champion of Device Development
An interview with Eberhard Grube, one of Germany's leading interventional cardiologists and a pioneer in medical devices who's had a role in changing the mindset of European physicians to bring together clinical practice and new product development. Grube discusses the role of the physician as clinical investigator, and the European perspective on product development.
Vulnerable Plaque: Medical Device's New Biological Frontier
As interest in vulnerable plaque heats up, medical device companies hope to capitalize on their earl y lead. But as vulnerable plaque shifts therapies from structural to biological, that lead many not last long. The second of a two-part series.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.